Co- and multipathologies need serious consideration for understanding Parkinson's disease pathogenesis and designing novel experimental therapeutic strategies
Parkinson ’ s disease (PD) is pathologically de fi ned by the presence of aggregated α -synuclein in the form of Lewy bodies and Lewy neurites. 1 – 4 Considerable interest has focused on anti-α -synuclein immunotherapy as a potential disease-modifying strategy for PD, but initial phase 2a clinical trials examining this...